Clinical trial
Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine
NCT00146835 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00146835 |
|---|---|
| Title | Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine |
| Official title | Phase IV, Prospective Study of the Safety of GSK Bios' Pediarix Administered to a Cohort of Infants in a US Health Maintenance Organization (HMO). (Post-Marketing PEDIARIX Safety Study) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Collaborators | Kaiser Permanente University of California, Los Angeles |
| Status | Completed |
| Study type | Observational |
| Conditions | Hepatitis B, Poliomyelitis, Diphtheria, Tetanus, Acellular Pertussis |
| Intervention type | Biological |
| Interventions | Pediarix, Licensed DTPa containing vaccine, Prevnar®: (Wyeth) |
| Enrollment | 120,794 |
| Start date | Apr 1, 2003 |
| Primary completion | Jun 1, 2006 |
| Completion | Jun 1, 2006 |
| First posted | Sep 7, 2005 |
| Last update posted | Jan 13, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: